NEW YORK, Nov. 12, 2013 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of ViroPharma, Inc. ("ViroPharma" or the "Company") (NasdaqGS: VPHM) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Shire PLC ("Shire").
Click here to learn more about the investigation http://zlk.9nl.com/viropharmavphm/ , or call: 877-363-5972. There is no cost or obligation to you.
ViroPharma and Shire announced on November 11, 2013, that the companies have entered into a definitive merger agreement under which Shire will acquire all the outstanding common stock of ViroPharma for approximately $4.2 billion. ViroPharma shareholders will receive $50 for each share of ViroPharma stock they own. The investigation concerns whether the ViroPharma Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Shire is underpaying for ViroPharma shares.If you own ViroPharma common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/viropharmavphm/ . Levi & Korsinsky is a national firm with offices in New York, New Jersey, Stamford, Connecticut and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Levi & Korsinsky, LLP Joseph Levi, Esq. Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com SOURCE Levi & Korsinsky, LLP
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV